BioPharmSignal logoBioPharmSignal

Biotech News

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

FEMASYS (FEMY)FEMASYSCommercial

First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients

Related news

FEMYFEMASYS2026-09-09 13:00 EST

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

FEMYFEMASYS2026-08-26 13:00 EST

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

HYPRHyperfine2026-08-26 12:15 EST

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

IARTIntegra LifeSciences2026-10-02 12:00 EST

Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B

RXSTRxSight2026-10-19 13:00 EST

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

ICUSeaStar Medical2026-10-05 12:00 EST

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

ADPTAdaptive Biotechnologies2026-09-25 12:03 EST

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

View all latest news

FEMASYS

Women's Health Medical Device Company Femasys develops office-based products for reproductive health. Its portfolio addresses permanent contraception, infertility treatment, and diagnostic evaluation of the uterus and fallopian tubes. FemBloc Permanent Contraception FemBloc is a non-surgical permanent birth-control system delivered...

Recent company news

FEMYFEMASYS2026-10-20 13:00 EST

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

FEMYFEMASYS2026-10-14 13:00 EST

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

FEMYFEMASYS2026-10-08 13:00 EST

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

FEMYFEMASYS2026-09-15 13:00 EST

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

FEMYFEMASYS2026-09-09 13:00 EST

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Stock data

Close
1.65 USD
Market cap
22.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States